

Patient Information	Prescriber + Shipping Information
Patient name: _____ DOB: _____	Prescriber name: _____
Sex: <input type="checkbox"/> Female <input type="checkbox"/> Male SSN: _____	NPI: _____
Language: _____ Wt: _____ <input type="checkbox"/> kg <input type="checkbox"/> lbs Ht: _____ <input type="checkbox"/> cm <input type="checkbox"/> in	Address: _____
Address: _____	Apt/Suite: _____ City: _____ State: _____ Zip: _____
Apt/Suite: _____ City: _____ State: _____ Zip: _____	Contact: _____
Phone: _____ Alternate: _____	Phone: _____ Alternate: _____
Caregiver name: _____ Relation: _____	Fax: _____
Local pharmacy: _____ Phone: _____	Email: _____
Insurance plan: _____ Plan ID: _____	If shipping to prescriber: <input type="checkbox"/> First Fill <input type="checkbox"/> Always <input type="checkbox"/> Never

Please fax a copy of front and back of the insurance card(s).

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis: L20.____ (Atopic Dermatitis) L40.0 (Psoriasis vulgaris/Plaque Psoriasis/Nummular Psoriasis) L40.8 (Other psoriasis)
 L40.9 (Psoriasis, unspecified) L40.5____ (Psoriatic arthritis) L73.2 (Hidradenitis Suppurativa) _____

Diagnosis Date: _____ TB test: Yes No Neg. Test Date: _____ HBV: Yes No If yes, currently treated: Yes No
 BSA affected (%): _____ Affected areas: Palms Soles Head Neck Genitalia _____

Prior Therapy <input type="checkbox"/> Yes <input type="checkbox"/> No	Reason for Discontinuation of Therapy	Approximate Start Date	Approximate End Date
_____	_____	_____	_____
_____	_____	_____	_____
_____	_____	_____	_____

Comorbidities: _____
 Concomitant Medications: _____
 Allergies: NKDA Other: _____

Has the patient received their starter dose(s)/kit? Yes; Start Date _____ No

Prescription	Quantity	PFS	Refill
Cimzia® (certolizumab) <i>Psoriatic Arthritis</i>	<input type="checkbox"/> Inject 400 mg subcut at weeks 0, 2 and 4	6 x 200 mg/mL	PFS Vials 0
	<input type="checkbox"/> Inject 200 mg subcut every 2 weeks	2 x 200 mg/mL	PFS Vials _____
	<input type="checkbox"/> Inject 400 mg subcut every 4 weeks		
Cosentyx® (secukinumab)	Inject 150 mg subcut once weekly at weeks 0, 1, 2 and 3	4 x 150 mg/mL	Sensoready® Pen PFS 0
	Inject 300 mg subcut once weekly at weeks 0, 1, 2 and 3	8 x 150 mg/mL	PFS _____
	Inject 150 mg subcut on week 4 and every 4 weeks thereafter Inject 300 mg subcut on week 4 and every 4 weeks thereafter	1 x 150 mg/mL 2 x 150 mg/mL	Sensoready® Pen PFS _____
Dupixent® (dupilumab)	Inject 600 mg subcut on day 1	2 x 300 mg/2 mL	PFS 0
	Inject 300 mg subcut at day 15 and every 2 weeks thereafter	2 x 300 mg/2 mL	PFS _____
Enbrel® (etanercept) <i>Adult</i>	<input type="checkbox"/> Inject 50 mg subcut twice a week (72-96 hours apart) for 3 months	8 x 50 mg/mL	SureClick® Autoinjector Mini™ Cartridge PFS 2
	Inject 50 mg subcut every week	4 x 50 mg/mL	SureClick® Autoinjector Mini™ Cartridge PFS _____
Enbrel® (etanercept) <i>Pediatric (4-17 yrs)</i>	Inject _____ mg (0.8mg/kg x _____ kg subcut every week (≤ 63 kg)	____ x 25 mg/mL	<input type="checkbox"/> Vials <input type="checkbox"/> PFS _____
	Inject 50 mg subcut every week (> 63 kg)	4 x 50 mg/mL	<input type="checkbox"/> SureClick® Autoinjector <input type="checkbox"/> Mini™ Cartridge PFS _____

§Humira®, Orenia®, Otezla®, Siliq™, Simponi®, Simponi Aria®, Stelara®, Taltz®, Tremfya™, Xeljanz® and Xeljanz® XR are listed alphabetically on respective enrollment forms.§

Injection Training Provided by: Physician's Office Pharmacy Other: _____

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____

Stamp signature not allowed, physician signature required.

Prescriber's Signature: _____ Date: _____

I authorize Diplomat Pharmacy, Inc. and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Diplomat Pharmacy, Inc.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 810.768.9178 or by emailing compliance@diplomat.is to obtain instructions as to the proper destruction of the transmitted material. Thank you.